BOSTON — For a closer look at Wednesday’s meningitis outbreak hearings, and what questions remain, Harvard’s Daniel Carpenter, who specializes in regulatory law, joined WBUR.

WASHINGTON — Barry Cadden told lawmakers he would use his Fifth Amendment right to not answer questions in order to avoid self-incrimination.

BOSTON — Recently released documents show that over the past decade the state did not aggressively pursue action against the center, despite complaints.

BOSTON — Massachusetts lawmakers grilled Patrick administration leaders and regulators about what went wrong in the oversight of a pharmacy at the center of a meningitis outbreak.

BOSTON — In 2004, the company protested that a penalty could destroy its business, and in 2006, the pharmacy board agreed to impose far weaker action for reasons that remain unclear.

BOSTON — Hearings get underway Wednesday at the Massachusetts State House and in Washington to look into the fungal meningitis outbreak that originated at a Framingham compounding pharmacy.

WASHINGTON — In 2003, the FDA suggested that the firm at the center of the meningitis outbreak be shut down but deferred to their counterparts in Mass., who let the pharmacy continue manufacturing.

WASHINGTON — Inspectors found numerous potential sources of contamination at the Westborough drug-making facility that has the same founders as the pharmacy linked to a meningitis outbreak.

BOSTON — Three hearings in Boston and Washington, D.C. will focus on whether a deadly outbreak of fungal meningitis traced to a Framingham compounding pharmacy could have been prevented.

BOSTON — The director was fired for ignoring a complaint that a Framingham company linked to a deadly meningitis outbreak was shipping drugs in bulk, in violation of its state license.

WASHINGTON — The subpoena comes after Barry Cadden, co-founder of New England Compounding Center, reportedly declined to appear before Congress next week.

BOSTON — Regulators ordered all pharmacists and technicians who worked at the company at the center of the meningitis outbreak to stop working in the drug-compounding industry.

BOSTON — Federal regulators say that further testing has found bacteria in products made by a Framingham pharmacy linked to the deadly fungal meningitis outbreak.

BOSTON — The emergency regulations allow the state to monitor whether the specialty pharmacies are operating more like drug manufacturing facilities.

BOSTON — Lawmakers will hold hearings looking into the Department of Public Health’s handling of the meningitis outbreak and drug lab scandal.

BOSTON — Ameridose is a sister company of New England Compounding Center, the pharmacy at the center of the meningitis outbreak.

BOSTON — The firm sent customers a “report card” touting the cleanliness of its labs, even though internal tests showed widespread contamination.

BOSTON — The Department of Public Health shut down a compounding pharmacy in Waltham after a surprise inspection prompted by the nationwide meningitis outbreak linked to a different company.

BOSTON — The FDA found mold and bacteria in two so-called “clean rooms” in the Framingham specialty pharmacy linked to the nationwide meningitis outbreak.

BOSTON — State officials say they found unclean conditions including visible black particle matter in vials of the recalled injectable steroid.